Stock ScreenerStock IdeasSmall Cap GrowthBest Small Cap Growth Stocks 2025Companies with small market capitalization and a 5 year track record of explosive revenue growth
Stock ScreenerStock IdeasSmall Cap Growth
Market Cap: $50M - $2B
Accelerating Revenue Growth: Pass
Revenue Growth vs Industry: Pass
Revenue Growth vs Market: Pass
| Ticker | Company | Zen Rating | Value | Growth | Momentum | Sentiment | Safety | Financials | AI | 1w Zen Rating | 1m Zen Rating | 3m Zen Rating | 1y Zen Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KROS | KEROS THERAPEUTICS INC | C | C | C | C | A | F | C | C | C | C | C | D |
| SPRY | ARS PHARMACEUTICALS INC | F | C | D | D | D | F | C | D | F | F | F | C |
| IPSC | CENTURY THERAPEUTICS INC | D | D | C | C | C | D | C | D | D | D | C | C |
| CANG | CANGO INC | C | D | A | C | B | D | C | C | C | C | C | – |
| XFOR | X4 PHARMACEUTICALS INC | D | D | C | C | C | D | D | D | D | D | D | D |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have access to Premium? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.